logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q1 2020
Blueprint Medicines
Submission of NDA for BLU-667
Non-small cell lung cancer previously treated with platinum-based chemotherapy
after Q1 2020
Blueprint Medicines
Submission of NDA for BLU-667
RET-mutant medullary thyroid cancer previously treated with an approved multi-kinase inhibitor
after Q1 2020
PhaseBio Pharmaceuticals Inc
Results from Phase 2b clinical trial of PB1046
Pulmonary Arterial Hypertension
after Q1 2020
VANDA PHARMACEUTICALS
Results from Phase III study of Tradipitant ((EPIONE)
Atopic dermatitis
Q1 2020
Evelo Biosciences, Inc.
Topline data from phase 1b trial of EDP1066
Atopic Dermatitis or Psoriasis
Early 2020
Evelo Biosciences, Inc.
Topline data from phase 1b trial of EDP1815
Atopic Dermatitis or Psoriasis
2020
Molecular Templates Inc.
Final data from phase II study of MT-3724 as a single agent
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Q1 2020
Equillium Inc.
Data from phase Ib/II clinical trial of EQ001 (EQUATE)
Patients with aGVHD
2020
Hemispherx Biopharma, Inc.
Data from phase IIa study combining Ampligen, Intron A and celecoxib
Colorectal cancer
2020
Hemispherx Biopharma, Inc.
Data from phase I study combining Ampligen, Intron A, celecoxib and pembrolizumab
Triple negative breast cancer
after Q1 2020
Zynerba Pharmaceuticals, Inc.
Top-line data from phase II study of Zygel (BRIGHT)
Autism Spectrum Disorder in children and adolescents
2020
Syros Pharmaceuticals
Potential proof-of-concept data from additional cohort in Phase 2 trial evaluating safety and efficacy of SY-1425 in combination with azacitidine
RARA or IRF8 biomarker-positive patients with relapsed or refractory AML
Q1 2020
Ovid Therapeutics Inc.
Data from phase II trial of OV935 (ARCADE)
Dup15q syndrome or CDKL5 Deficiency Disorder
2020
Agile Therapeutics Inc.
Topline data from phase III trial of Efgartigimod (ADAPT)
Myasthenia gravis
2020
argenx SE
Data from phase II proof-of-concept clinical trial of Efgartigimod
Pemphigus vulgaris
2020
Galapagos NV..
Results from phase II trial of GLPG1972/S201086 (ROCCELLA)
Knee osteoarthritis
after Q1 2020
Seattle Genetics Inc.
Topline data from pivotal trial of Tisotumab vedotin(innovaTV 204)
Recurrent and/or metastatic cervical cancer
Jan 2020
Acasti Pharma, Inc.
Top line results from phase III trial to evaluate safety and efficacy of CaPre (TRILOGY 2)
Severe hypertriglyceridemia
after Q1 2020
Milestone Pharmaceuticals Inc
Top-line data from phase III trial of Etripamil
Paroxysmal supraventricular tachycardia (PSVT)
Q1 2020
Acceleron Pharma, Inc
Data from phase II study of ACE-083
Charcot-Marie-Tooth disease
Q1 2020
Acceleron Pharma, Inc
Topline results from phase II trial of Sotatercept (PULSAR)
Pulmonary arterial hypertension
after Q1 2020
Revance Therapeutics, Inc.
Topline results from phase II trial of DaxibotulinumtoxinA for Injection
Forehead lines
after Q1 2020
Revance Therapeutics, Inc.
Topline results from phase II trial of DaxibotulinumtoxinA for Injection
Crow's feet
after Q1 2020
Novus Therapeutics, Inc.
Report results from phase 2a study of OP0201
Acute otitis media
after Q1 2020
Harpoon Therapeutics Inc.
Interim results from phase I clinical trial of HPN424
Metastatic castration-resistant prostate cancer
>